stockportfolio.pro
Viatris Inc. (VTRS)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Viatris Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.43B | $11.50B | $11.95B | $17.89B | $16.26B | $15.43B | $14.74B | $14.30B |
| Gross profit | $4.00B | $3.90B | $3.80B | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B |
| Net income | $352.50M | $16.80M | $-669.90M | $-1.27B | $2.08B | $54.70M | $-634.20M | $-3.51B |
| Net margin | 3.1% | 0.1% | -5.6% | -7.1% | 12.8% | 0.4% | -4.3% | -24.6% |
Source: Viatris Inc. SEC filings (10-K).
What growth is priced into VTRS stock?
At today's market cap of $18.87B, Viatris Inc. is priced for free-cash-flow growth of about -2.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.94B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 14.4%/yr over the last five fiscal years and revenue 3.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 8 years of Viatris Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VTRS in your portfolio →
Viatris Inc. financial history by metric
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Viatris Inc. — frequently asked questions
What is Viatris Inc.'s revenue?
Viatris Inc. (VTRS) reported revenue of $14.30B for fiscal year 2025, down 3.0% from the prior year, according to its SEC filings.
Is Viatris Inc. profitable?
No — VTRS reported a net loss of $-3.51B in fiscal 2025.
What is VTRS's P/E ratio?
Viatris Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Viatris Inc. growing?
VTRS's revenue grew at roughly 3.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Viatris Inc. have?
As of fiscal year 2025, VTRS carried roughly $14.41B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Viatris Inc.'s gross margin?
VTRS's gross margin was 35.1% in fiscal 2025 — gross profit of $5.01B on revenue of $14.30B.
What is Viatris Inc.'s market cap?
Viatris Inc. (VTRS) has a market capitalization of about $18.87B, based on the latest data in our nightly-refreshed cache.
When does Viatris Inc.'s fiscal year end?
VTRS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into VTRS stock?
At today's market cap of $18.87B, Viatris Inc. is priced for free-cash-flow growth of about -2.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.94B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 14.4%/yr over the last five fiscal years and revenue 3.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Viatris Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.